Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 4Pain 4Neoplasms 4Nausea 3Pancreatic Neoplasms 2Cancer Pain 2Breast Neoplasms 2Taste Disorders 1Parasomnias 1Olfaction Disorders 1Marijuana Abuse 1Malnutrition 1Lung Neoplasms 1Head and Neck Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Anxiety Disorders 1Anorexia 1

Interventions

Music Therapy 15Therapeutics 14Surveys and Questionnaires 13Cognitive Behavioral Therapy 13Psychiatric Rehabilitation 12Methods 9Standard of Care 8Educational Status 8Early Intervention, Educational 8Psilocybin 7Mindfulness 6Ketamine 6Hypnosis 6Control Groups 6Aromatherapy 6Acupuncture Therapy 6Mindfulness-Based Stress Reduction 5Mindfulness-Based Cognitive Therapy 5Massage 5Counseling 5Art Therapy 5Saline Solution 4Interviews as Topic 4Imagery, Psychotherapy 4Esketamine 4Caregivers 4Behavior Therapy 4Autogenic Training 4Yoga 3Weights and Measures 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anxiety Disorders × Dronabinol × Clear all
NCT03948074 2025-09-10

CAFCARS

British Columbia Cancer Agency

Phase 2 Completed
91 enrolled

Anxiety Disorders, Nausea, Pain, Parasomnias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡